Illumina’s Acquisition of SomaLogic

On June 23, 2025, Illumina, Inc. (“Illumina”) announced it has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data‑driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance‑based milestones and performance‑based royalties. Cravath is representing Illumina in connection with the transaction.

The Cravath team is led by partners Ting S. Chen and Daniel J. Cerqueira and includes of counsel Saagar Kaul, associates Matthew C. Weinstein, Joseph N. Kadoch, Victoria Gu and Nicholas J. Juan and foreign associate attorney Alberto Giavaldi on M&A matters; partner Ron Creamer and associate Christopher M. Winters on tax matters; partner Matthew J. Bobby, senior attorney Aaron S. Cha, practice area attorney David Crampton and associate Matthew S. Johnson on executive compensation and benefits matters; partners Noah Joshua Phillips and Jesse M. Weiss and associates Lavinia M. Hecht and Shuyu Sun on antitrust matters; partner David J. Kappos, of counsel Kathryn-Ann Stamm, associates Albert Wong and Vincent Joralemon and foreign associate attorney Shogo Tsunoda on intellectual property matters; partner Matthew Morreale and associate Star S. Gulant on environmental matters; and practice area attorney Lauren Piechocki on real estate matters. Summer associates Istvan Zain Kovach and Amanda Suzuki also worked on M&A matters.